What Are the Treatment Options for Early-Stage Cancer?
Lurbinectedin, also known as PM1183, is a second-generation DNA minor groove alkylator, developed for the treatment of various types of cancer, including small cell lung cancer (SCLC). While it is primarily investigated for advanced stages of cancer, the potential of using lurbinectedin in early-stage cancer is also being explored.
When Is Lurbinectedin Used?
Lurbinectedin received FDA accelerated approval in 2019 for the treatment of adult patients with SCLC with disease progression on or after platinum-based chemotherapy, including patients with tumors harboring specific aberrations. This approval was primarily based on data from the phase 1b/2 single-arm trial, CITE (NCT01663773) [1], which demonstrated the efficacy and safety of lurbinectedin in patients with platinum-resistant SCLC.
Can Lurbinectedin Be Used in Early-Stage Cancer?
Current clinical trials are focused on evaluating the efficacy of lurbinectedin in patients with advanced stages of cancer. While there is no established use of lurbinectedin in early-stage cancer, researchers are investigating its potential as a frontline treatment or in conjunction with chemotherapy for SCLC.
How Does Lurbinectedin Compare with Other Treatments for Early-Stage Cancer?
Comparative studies between lurbinectedin and other cancer treatments in early-stage cancer are limited. However, researchers believe that the unique mechanism of action of lurbinectedin, which targets cancer cells through DNA damage and apoptosis, may offer a distinct advantage over traditional chemotherapy.
What Are the Side Effects of Lurbinectedin in Early-Stage Cancer?
The side effect profile of lurbinectedin in early-stage cancer is not well established, as most clinical data are from advanced cancer trials. However, researchers anticipate that the adverse effects may be comparable to those observed in advanced cancer trials, which include myelosuppression, fatigue, neutropenia, anemia, thrombocytopenia, gastrointestinal symptoms, and sensory neuropathy [2].
What Is the Potential for Lurbinectedin to Be Used in Early-Stage Cancer?
The potential for lurbinectedin to be used in early-stage cancer is promising, given its unique mechanism of action and the need for novel treatments that can improve outcomes in this challenging disease. Additional clinical trials are necessary to establish the efficacy and safety of lurbinectedin in early-stage cancer.
References:
[1] Caldas-Lopes, E., 2017. Lurbinectedin (PM1183) as a novel anticancer agent. Expert Opin Investig Drugs 26 (2), 247-255. doi: 10.1080/13543784.2017.126. DrugPatentWatch.com
[2] de Almagro, M. C., et al., 2020. Lurbinectedin (PM1183): a review of its chemistry, mechanism of action, and clinical trials in cancer. J Exp Clin Cancer Res 39 (1), 137. doi: 10.1186/s13046-020-01654-2.
Sources:
1. DrugPatentWatch.com (PM1183)
2. National Institutes of Health (NCT01663773)
3. Journal of Experimental and Clinical Cancer Research